相关实验视频
Updated: Jan 22, 2026

10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
2.3K
抗B细胞成熟抗原 仿真抗原受体 T细胞治疗 bb21217 复发性和耐火性多发性骨髓瘤:第一阶段CRB-402研究的结果
Melissa Alsina1, Nina Shah2, Sundar Jagannath3
1Moffitt Cancer Center Tampa, FL United States.
Cancer immunology research
|January 21, 2026
概括
化学抗原受体 (CAR) 丰富T细胞疗法用于记忆细胞显示在多发性骨髓瘤中反应的持续时间有所改善. 早期的CAR T细胞生成可能会为患者最大限度地提高临床效益.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法 细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞疗法是多发性骨髓瘤的一种有前途的治疗方法.
- 提高T细胞的持续性和功能对于改善长期患者的治疗结果至关重要.
- 一种类似记忆的T细胞表型与改善的CAR T细胞疗效有关.
研究的目的:
- 为了评估bb21217的安全性和有效性,CAR T细胞疗法为一种类似记忆的表型进行了丰富.
- 在接受 bb21217.治疗的复发性/耐药性多发性骨髓瘤患者中评估反应的持续时间 (DOR).
- 探索T细胞表型,扩张和临床反应之间的关联.
主要方法:
- 一期临床试验 (NCT03274219) 涉及72名复发/耐药多发性髓瘤患者.
- bb21217 CAR T细胞疗法用酸酸3-激酶抑制剂 (bb007) 制造,以丰富类似记忆的T细胞.
- 安全性评估,客观响应率 (ORR) 和DOR.
主要成果:
- bb21217的客观反应率为69.4%,DOR的中位数为23.8个月.
- 没有发现新的安全问题;三级以上的细胞因子释放综合征 (CRS) 和神经毒性发生在三名患者中.
- 一个早期的记忆表型与强大的CAR T细胞扩张和更深层次的反应相关.
结论:
- bb21217 CAR T细胞疗法对复发性/耐药性多发性骨髓瘤是安全有效的,提供了长期的 DOR.
- 为一种类似记忆的T细胞表型进行丰富,可以增强CAR T细胞的持久性和功能.
- 在疾病过程中早期生成CAR T细胞可以通过利用更天真的T细胞来源和较低的瘤负担来优化临床益处.
相关概念视频
Antigen Presenting Cells
3.0K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.0K
Diversity of Antigen Receptors
1.4K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.4K
Antigen Processing Pathways
2.1K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
2.1K
Antigens Involved in Adaptive Immunity
1.3K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.3K
Drug Administration and Therapy Phases: Overview
1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
Types of Receptors: Cell Surface Receptors
26.8K
Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored (integral) proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal. Ligands that interact with cell-surface receptors do not have to enter the cell that they affect. Cell-surface receptors are also called cell-specific proteins or markers because they are...
26.8K

